Federal Register / Vol. 65, No. 10 / Friday, January 14, 2000 / Notices 2415

grant. An enclosure with every grant

award provides instructions on

completing and submitting the OPR.

Native American Program Specialists

use the OPR information to perform

legislatively required Federal program

oversight such as evaluate project and

grantee performance, identify project

outcomes suitable for use in program

evaluation and Government

Performance and Results Act (GPRA)

analysis, and to identify grantees and

projects that require more detailed

Federal training and/or technical

assistance. OPRs are used in ANA

competitive grant programs such as

Social and Economic Development

Strategies (SEDS), Native American

Languages Preservation, Environmental

Regulatory Enhancement, etc.

The Administration for Native

Americans simplified the way OPR

information is collected. Until June

1999, OPRs were transcribed onto a

government designed form where every

project objective was listed; grantees

often worked to fill in space under each

objective to accommodate the volume of

information they believed was required.

Grantees now use their letterhead and

present the level of detail they deem

appropriate.

Respondents: State, Local or Tribal

Government.

ANNUAL BURDEN ESTIMATES

Instrument Number of

respondents

Number of

responses

per

respondent

Average

burden

hours per

response

Total

burden

hours

Objective Progress Report (OPR) ................................................................................... 300 2 1.5 900

Estimated Total Annual Burden

Hours: 900.

Additional Information: Copies of the

proposes collection may be obtained by

writing to the Administration for

Children and Families, Office of

Information Services, Division of

Information Resource Management

Services, 370 L’Enfant Promenade, S.W.,

Washington, D.C. 20447, Attn: ACF

Reports Clearance Officer.

OMB Comment: OMB is required to

made a decision concerning the

collection of information between 30 to

60 days after publication of this

document in the Federal Register.

Therefore, a comment is best assured of

having its full effect if OMB receives it

within 30 days of publication. Written

comments and recommendations for the

proposed information collection should

be sent directly to the following: Office

of Management and Budget, Paperwork

Reduction Project, 725 17th Street,

N.W., Washington, D.C. 20503, Attn:

ACF Desk Officer.

Dated: January 10, 2000.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 00–879 Filed 1–13–00; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Obstetrics and Gynecology Devices

Panel of the Medical Devices Advisory

Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). At least one portion of the

meeting will be closed to the public.

Name of the Committee: Obstetrics

and Gynecology Devices Panel of the

Medical Devices Advisory Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on

FDA’s regulatory issues.

Date and Time: The meeting will be

held on January 24, 2000, from 9 a.m.

to 6 p.m., and January 25, 2000, from 8

a.m. to 5 p.m.

Location: Holiday Inn, Walker/

Whetstone Rooms, Two Montgomery

Village Ave., Gaithersburg, MD.

Contact Person: Elisa D. Harvey,

Center for Devices and Radiological

Health (HFZ–470), Food and Drug

Administration, 9200 Corporate Blvd.,

Rockville, MD 20850, 301–594–1180, or

FDA Advisory Committee Information

Line, 1–800–741–8138 (or 301–443–

0572 in the Washington, DC area), code

12524. Please call the Information Line

for up-to-date information on this

meeting.

Agenda: On January 24, 2000, the

committee will discuss, make

recommendations, and vote on a

premarket approval application for a

fetal pulse oximeter. On January 25,

2000, the committee will discuss a draft

guidance document on adhesion barrier

products intended for use in pelvic and/

or abdominal surgery. The draft

guidance document is available to the

public on the Internet at http://

www.fda.gov/cdrh/ode/resorbable.pdf

and http://www.fda.gov/cdrh/ode/

1356.html, or by contacting CDRH

Facts-on-Demand at 1–800–899–0381 or

301–827–0111, specify number 1356

when prompted for the document shelf

number.

Procedure: On January 24, 2000, from

9 a.m. to 6 p.m., and January 25, 2000,

from 9 a.m. to 5 p.m., the meeting is

open to the public. Interested persons

may present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by January 20, 2000. Oral

presentations from the public will be

scheduled between approximately 9:15

a.m. and 9:45 a.m. and 5 p.m. and 5:30

p.m. on January 24, 2000, and between

approximately 9:30 a.m. and 10 a.m. on

January 25, 2000. Time allotted for each

presentation may be limited. Those

desiring to make formal presentations

should notify the contact person before

January 20, 2000, and submit a brief

statement of the general nature of the

evidence or arguments they wish to

present, the names and address of

proposed participants, and an

indication of the approximate time

requested to make their presentation.

Closed Committee Deliberations: On

January 25, 2000, from 8 a.m. to 9 a.m.,

the meeting will be closed to the public.

The committee will hear and review

trade secret and/or confidential

commercial information on pending and

future applications under review. This

portion of the meeting will be closed to

permit discussion of this information (5

U.S.C. 552b(c)(4)).

FDA regrets that it was unable to

publish this notice 15 days prior to the

January 25, 2000, Obstetrics and

Gynecology Devices Panel of the

Medical Devices Advisory Committee

meeting. Because the agency believes

there is some urgency to bring these

issues to public discussion and

qualified members of the Obstetrics and

2416 Federal Register / Vol. 65, No. 10 / Friday, January 14, 2000 / Notices

Gynecology Devices Panel of the

Medical Devices Advisory Committee

were available at this time, the

Commissioner of Food and Drugs

concluded that it was in the public

interest to hold this meeting even if

there was not sufficient time for the

customary 15-day public notice.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: January 10,2000

Linda A. Suydam,

Senior Associate Commissioner

[FR Doc. 00–981 Filed 1–13–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Peripheral and Central Nervous

System Drugs Advisory Committee;

Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing an

amendment to the notice of a meeting of

the Peripheral and Central Nervous

System Drugs Advisory Committee. This

meeting was announced in the Federal

Register of December 27, 1999 (64 FR

72355). The amendment is being made

to cancel the entire session on January

27, 2000. This meeting will be open to

the public. There are no other changes.

FOR FURTHER INFORMATION CONTACT:

Sandra L. Titus, Center for Drug

Evaluation and Research (HFD–21),

Food and Drug Administration, 5600

Fishers Lane (for express delivery, 5630

Fishers Lane, rm. 1093) Rockville, MD

20857, 301–827–7001, or e-mail

tituss@cder.fda.gov, or FDA Advisory

Committee Information Line, 1–800–

741–8138 (301–443–0572 in the

Washington, DC area) code 12543.

Please call the Information Line for upto-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the

Federal Register of December 27, 1999

(64 FR 72355), FDA announced that a

meeting of the Peripheral and Central

Nervous System Drugs Advisory

Committee would be held on January 27

and 28, 2000. On page 72355, beginning

in the first column, the Date and Time,

Agenda, and Procedure portions of this

meeting are amended to read as follows:

Date and Time: The meeting will be

held January 28 from 8 a.m. to 5 p.m.

Location: Hilton, 620 Perry Ave.,

Gaithersburg, MD.

Agenda: On January 28, the

committee will consider the safety and

efficacy of new drug NDA 21–120,

Novantrone , (mitoxantrone, Immunex

Corporation) proposed to treat

secondary progressive multiple

sclerosis, including progressive

relapsing disease.

Procedure: Interested persons may

present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by January 20, 2000. Oral

presentations from the public will be

scheduled between approximately 1

p.m. and 2 p.m. on both days. Time

allotted for each presentation may be

limited. Those desiring to make formal

oral presentations should notify the

contact person before January 20, 2000,

and submit a brief statement of the

general nature of the evidence or

arguments they wish to present, the

names and addresses of proposed

participants, and an indication of the

approximate time requested to make

their presentation.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: January 7, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 00–889 Filed 1–13–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Indian Health Service

Request for Public Comment: 60-Day

Notice; Proposed Collection:

Evaluation of Indian Health Service/

Bureau of Indian Affairs Training

Practitioners Project

SUMMARY: In compliance with Section

3506(c)(2)(A) of the Paperwork

Reduction Act of 1995, to provide a 60-

day advance opportunity for public

comment on proposed information

collection projects, the Indian Health

Service is publishing for comment a

summary of a proposed information

collection to be submitted to the Office

of Management and Budget (OMB) for

review.

PROPOSED COLLECTION: Title:

‘‘Evaluation of Indian Health Service

/Bureau of Indian Affairs Training

Practitioners Project.’’ Type of

Information Collection Request: New

collection. Form Number: None. Need

and Use of Information Collection: The

purpose of the proposed data collection

is to evaluate and assess the overall

effectiveness of the Indian Health

Service (IHS) and Bureau of Indian

Affairs (BIA) inter-agency sponsored

national training project titled, ‘‘IHS/

BIA Training Practitioners in the

Assessment and Treatment of

Adolescent Sexual Perpetrators,’’

conducted from 1993–1996 in 18

American Indian/Alaska Native (AI/AN)

communities. The training project was

established to provide mental health

practitioners in AI/AN communities

specialized training for the provision of

mental health assessment and treatment

services to juvenile sex offenders. The

data collected is needed to assess

respondent satisfaction/dissatisfaction

with the training project, the clinical

success/failure of the training on the

juvenile sex offenders, the impact of

using traditional healing treatment

services with juvenile sex offenders, and

to obtain recommendations for future

clinical program planning. Affected

Public: Individuals and households,

State, Local or Tribal Government. Type

of Respondents: Health care providers,

juveniles, parent/caretakers, and various

community members. Please see Table 1

for a listing of data collection

instruments, estimated number of

respondents, number of responses per

respondent, annual number of

responses, average burden hour per

response, and total annual burden hour.

TABLE 1

Date collection instruments

Estimated

No. of

respondents

Reponses

per

respondent

Annual

Number of

respondents*

Average

burden

hour per

response*

Total annual

burden hours

Practitioner Trainee Questionnaire ........................................ 159 1 159 0.50 (30

mins).

79.5